<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Paul Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">Rev Paul Pediatr</journal-id><journal-id journal-id-type="publisher-id">rpp</journal-id><journal-title-group><journal-title>Revista Paulista de Pediatria</journal-title></journal-title-group><issn pub-type="ppub">0103-0582</issn><issn pub-type="epub">1984-0462</issn><publisher><publisher-name>Sociedade de Pediatria de S&#x000e3;o Paulo</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26826879</article-id><article-id pub-id-type="pmc">4795726</article-id><article-id pub-id-type="doi">10.1016/j.rppede.2015.06.019</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Continuous insulin therapy <italic>versus</italic> multiple insulin
injections in the management of type 1 diabetes: a longitutinal study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ribeiro</surname><given-names>Maria Estela Bellini</given-names></name></contrib><contrib contrib-type="author"><name><surname>Liberatore</surname><given-names>Raphael Del Roio</given-names><suffix>Junior</suffix></name><xref ref-type="corresp" rid="c1">*</xref></contrib><contrib contrib-type="author"><name><surname>Custodio</surname><given-names>Rodrigo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Martinelli</surname><given-names>Carlos Eduardo</given-names><suffix>Junior</suffix></name></contrib><aff>Universidade de S&#x000e3;o Paulo (USP), Ribeir&#x000e3;o Preto, SP, Brazil</aff></contrib-group><author-notes><corresp id="c1"><label>*</label> Corresponding author. <email>rliberatore@fmrp.usp.br</email> (R. Del
Roio Liberatore Junior).</corresp><fn fn-type="conflict"><p>
<bold>Conflicts of interest</bold>
</p><p>The author declares no conflicts of interest.</p></fn></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Mar</season><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2016</year></pub-date><volume>34</volume><issue>1</issue><fpage>86</fpage><lpage>90</lpage><history><date date-type="received"><day>12</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>9</day><month>6</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Sociedade de Pediatria de S&#x000e3;o Paulo. Published by Elsevier
Editora Ltda</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
cited.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective:</title><p>To compare multiple doses of insulin and continuous insulin infusion therapy as
treatment for type 1 diabetes mellitus.</p></sec><sec><title>Methods:</title><p>40 patients with type 1 diabetes mellitus (21 female) with ages between 10 and 20
years (mean=14.2) and mean duration of diabetes of 7 years used multiple doses of
insulin for at least 6 months and after that, continuous insulin infusion therapy
for at least 6 months. Each one of the patients has used multiple doses of insulin
and continuous insulin infusion therapy. For analysis of HbA1c, mean glycated
hemoglobin levels (mHbA1c) were obtained during each treatment period (multiple
doses of insulin and continuous insulin infusion therapy period).</p></sec><sec><title>Results:</title><p>Although mHbA1c levels were lower during continuous insulin infusion therapy the
difference was not statistically significant. During multiple doses of insulin,
14.2% had mHbA1c values below 7.5% <italic>vs</italic>. 35.71% while on continuous
insulin infusion therapy; demonstrating better glycemic control with the use of
continuous insulin infusion therapy. During multiple doses of insulin, 15&#x02013;40
patients have severe hypoglycemic events <italic>versus</italic> 5&#x02013;40 continuous
insulin infusion therapy. No episodes of ketoacidosis events were recorded.</p></sec><sec><title>Conclusions:</title><p>This is the first study with this design comparing multiple doses of insulin and
continuous insulin infusion therapy in Brazil showing no significant difference in
HbA1c; hypoglycemic events were less frequent during continuous insulin infusion
therapy than during multiple doses of insulin and the percentage of patients who
achieved a HbA1c less than 7.5% was greater during continuous insulin infusion
therapy than multiple doses of insulin therapy.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Type 1 diabetes mellitus</kwd><kwd>Insulin</kwd><kwd>Insulin infusion systems</kwd><kwd>Adolescents</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Diabetes mellitus (DM) is a chronic metabolic syndrome characterized by intense
catabolism. Type 1 diabetes mellitus (T1DM) is due to deficient insulin secretion, in
most cases after autoimmune destruction of pancreatic beta cells. It is a very frequent
chronic disease affecting children,<xref rid="B1" ref-type="bibr">1</xref> with
incidence increasing all over the world.<xref rid="B2" ref-type="bibr">2</xref> In this
way, diabetic ketoacidosis (DKA) and hypoglycemia are acute complications of T1DM
associated with variety adverse effects and both can have fatal effects if not reversed
in time.<xref rid="B3" ref-type="bibr">3</xref>
</p><p>The DCCT study (The Diabetes Control and Complications Trial Research Group)<xref rid="B4" ref-type="bibr">4</xref> demonstrated that intensive insulin therapy with
multiple doses of insulin (MDI) or with a continuous insulin infusion therapy (CIIT)
would be the best treatment for T1DM. In spite of the knowledge about both, MDI<xref rid="B5" ref-type="bibr">5</xref>
<sup>&#x02013;</sup>
<xref rid="B7" ref-type="bibr">7</xref> and CIIT,<xref rid="B7" ref-type="bibr">7</xref>
the comparison between these therapeutic schemes, particularly among children and
adolescents, is incipient. Several studies have suggested that CIIT may provide better
glycemic control,<xref rid="B8" ref-type="bibr">8</xref>
<sup>&#x02013;</sup>
<xref rid="B11" ref-type="bibr">11</xref> with lower risk of severe hypoglycemia and a
smaller weight gain<xref rid="B8" ref-type="bibr">8</xref> compared to the MDI therapy.
Among these analyses, few of these studies have been conducted on children and
adolescents.<xref rid="B9" ref-type="bibr">9</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">10</xref>
</p><p>The aim of the present study was to assess, in a comparative manner, the MDI therapy and
the use of CIIT regarding metabolic control and the occurrence of acute complications of
the disease in a sample of children and adolescents with T1DM followed up at a public
hospital in S&#x000e3;o Paulo state, Brazil.</p></sec><sec sec-type="methods"><title>Method</title><p>This was a longitudinal study based on data obtained retrospectively from the medical
records of patients of both sexes aged 5&#x02013;20 years with a diagnosis of T1DM according to
the International Society for Pediatric and Adolescent Diabetes criteria (ISPAD,
1995).</p><p>The patients had been using MDI for at least 6 months, and later CIIT, using both brands
available in Brazil, also for at least 6 months. The duration of diabetes was required
to be more than 2 years.</p><p>All patients were trained to count carbohydrates, to modify insulin dosage and to
measure capillary glucose levels 7&#x02013;9 times daily. They all have a telephone number to
make contact if they need, and the consultations were made every 3 months by a multi
professional team.</p><p>The following data were obtained: sex, age, time of MDI use, time of CIIT use, mean
glycated hemoglobin levels (mHbA1c), number of severe hypoglycemic events requiring help
for recovery, and number of DKA episodes. HbA1c levels were measured by HPLC and it was
the same method during all the study.</p><p>The research protocol was approved by the Research Ethics Committee with waiver of
informed consent.</p><p>Data are reported as mean (&#x000b1;SD) and median. The nonparametric Wilcoxon test was used for
the paired values of the variables, with the level of significance set at
<italic>p</italic>&#x0003c;0.05.</p></sec><sec sec-type="results"><title>Results</title><p>We analyzed the medical records of 40 patients, 46.4% of them males, who first used MDI
and later CIIT during the period from 2011 to 2012. At the time of data collection,
patient's age ranged from 10 years and eight months to 20 years and 2 months
(mean&#x000b1;standard deviation: 14&#x000b1;2.35 years). Time since the diagnosis of the disease ranged
from 2 years and 2 months to 15 years and 3 months (mean 7.0 years).</p><p>Time of MDI ranged from 8 months to 14 years and 9 months (mean&#x000b1;standard deviation:
5.1&#x000b1;3.6 months). Time of CIIT use ranged from 6 months to 4 years and 5 months
(mean&#x000b1;standard deviation: 1.4&#x000b1;3.6 years) (<xref ref-type="table" rid="t1">Table
1</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Mean glycated hemoglobin (mHbA1c) values (%) for the total sample (T), Mean
glycated hemoglobin for patients who were submitted to at least 1 year of each
treatment (1y) and 2 years of each treatment (2y).</title></caption><table frame="hsides" rules="groups" style="border-color:#376bad"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead style="background-color:#bad2ed;border-color:#376bad"><tr><th align="left" rowspan="1" colspan="1">mHbA1c (n=40)</th><th align="left" rowspan="1" colspan="1">Mean&#x000b1;SD</th><th align="left" rowspan="1" colspan="1">Median</th><th align="left" rowspan="1" colspan="1">
<italic>p</italic> -value <xref ref-type="table-fn" rid="TFN1">a</xref>
</th></tr></thead><tbody style="background-color:#e5edf8;border-color:#376bad"><tr><td align="left" rowspan="1" colspan="1">MDI (T)</td><td align="char" rowspan="1" colspan="1">9.1&#x000b1;2.0</td><td align="char" rowspan="1" colspan="1">8.6</td><td align="char" rowspan="1" colspan="1">0.55 <xref ref-type="table-fn" rid="TFN2">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CIIT (T)</td><td align="char" rowspan="1" colspan="1">8.9&#x000b1;2.5</td><td align="char" rowspan="1" colspan="1">8.2</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">MDI (1 y)</td><td align="char" rowspan="1" colspan="1">9.3&#x000b1;2.3</td><td align="char" rowspan="1" colspan="1">8.6</td><td align="char" rowspan="1" colspan="1">0.095 <xref ref-type="table-fn" rid="TFN3">c</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CIIT (1 y)</td><td align="char" rowspan="1" colspan="1">8.4&#x000b1;1.9</td><td align="char" rowspan="1" colspan="1">7.8</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">MDI (2 y)</td><td align="char" rowspan="1" colspan="1">8.4&#x000b1;0.9</td><td align="char" rowspan="1" colspan="1">8.4</td><td align="char" rowspan="1" colspan="1">0.67 <xref ref-type="table-fn" rid="TFN4">d</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">CIIT (2 y)</td><td align="char" rowspan="1" colspan="1">8.4&#x000b1;2.3</td><td align="char" rowspan="1" colspan="1">7.7</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>a</label><p>Single-sample nonparametric Wilcoxon test.</p></fn><fn id="TFN2"><label>b</label><p>Comparison between MDI and CIIT.</p></fn><fn id="TFN3"><label>c</label><p>Comparison between MDI and CIIT (1y).</p></fn><fn id="TFN4"><label>d</label><p>Comparison between MDI and CIIT (2y).</p></fn><fn id="TFN5"><p>SD, standard deviation; MDI, multiple doses of insulin; CIIT, continuous
insulin infusion therapy.</p></fn></table-wrap-foot></table-wrap><p>The data did not show variation according to sex.</p><p>For analysis of HbA1c levels, the results obtained during each treatment period (MDI and
CIIT) were retrieved and the mHbA1c value was calculated for each patient and each
period. The mean and the median mHbA1c values were then calculated for the sample and
for the period of each treatment. <xref ref-type="table" rid="t2">Table 2</xref> shows
the mHbA1c results obtained in the two periods. The data show that, although mHbA1c
levels were lower during the use of CIIT than during the use of MDI, no significant
difference was observed.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Mean glycated hemoglobin (mHbA1c) values (%) for patients with levels of less
than 7.5% during only one of the treatments.</title></caption><table frame="hsides" rules="groups" style="border-color:#376bad"><colgroup span="1"><col width="40%" span="1"/><col width="30%" span="1"/><col width="30%" span="1"/></colgroup><thead style="background-color:#bad2ed;border-color:#376bad"><tr><th align="left" rowspan="1" colspan="1">Patient</th><th align="left" rowspan="1" colspan="1">mHbA1c during MDI</th><th align="left" rowspan="1" colspan="1">mHbA1c during CIIT</th></tr></thead><tbody style="background-color:#e5edf8;border-color:#376bad"><tr><td align="left" rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1">7.85</td><td align="char" rowspan="1" colspan="1">7.1</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="char" rowspan="1" colspan="1">7.96</td><td align="char" rowspan="1" colspan="1">7.33</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="char" rowspan="1" colspan="1">7.9</td><td align="char" rowspan="1" colspan="1">6.87</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="char" rowspan="1" colspan="1">9.45</td><td align="char" rowspan="1" colspan="1">7.26</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="char" rowspan="1" colspan="1">8.33</td><td align="char" rowspan="1" colspan="1">7.26</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="char" rowspan="1" colspan="1">8.4</td><td align="char" rowspan="1" colspan="1">5.35</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="char" rowspan="1" colspan="1">8.61</td><td align="char" rowspan="1" colspan="1">7.5</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="char" rowspan="1" colspan="1">9.3</td><td align="char" rowspan="1" colspan="1">7.05</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="char" rowspan="1" colspan="1">7.1</td><td align="char" rowspan="1" colspan="1">7.5</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="char" rowspan="1" colspan="1">7.06</td><td align="char" rowspan="1" colspan="1">7.7</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="char" rowspan="1" colspan="1">7.1</td><td align="char" rowspan="1" colspan="1">7.8</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="char" rowspan="1" colspan="1">7.1</td><td align="char" rowspan="1" colspan="1">7.5</td></tr></tbody></table><table-wrap-foot><fn id="TFN6"><p>mHba1c, mean glycated hemoglobin for each patients; MDI, multiple daily insulin
injections; CIIT, continuous insulin infusion therapy.</p></fn></table-wrap-foot></table-wrap><p>Analysis of the data for patients who had used at least one year of each treatment
revealed that mHbA1c levels were 9.3 (&#x000b1;2.3)% during the MDI period (median: 8.6), and
8.4 (&#x000b1;1.9)% during the CIIT period, with a median of 7.8% (<italic>p</italic>=0.095),
showing that there was no significant difference in mHbA1c levels obtained during the
two treatments (<xref ref-type="table" rid="t1">Table 1</xref>).</p><p>Analysis of the data for patients who had used at least two years of each treatment
revealed that mHbA1c levels were 8.4 (&#x000b1;0.9%) during the MDI period, with a median of
8.4, and 8.4 (&#x000b1;2.3%) with a median of 7.7% during the period of use of CIIT. Again, the
Wilcoxon test showed no significant difference between periods (<italic>p</italic>=0.67)
(<xref ref-type="table" rid="t1">Table 1</xref>).</p><p>During the use of MDI, 14.2% had mHbA1c values below 7.5%, the value recommended by
ISPAD as target to metabolic control, and during the use of CIIT 35.71% had mHbA1c
values below 7.5%, demonstrating better glycemic control with the use of an infusion
pump for treatment.</p><p>Analysis of cases with less than 7.5% of mHbA1c levels in only one of the treatments
(MDI or CIIT) revealed that eight of the 12 patients (66.6%) showed reduced mHbA1c
levels when they switched to CIIT, while four patients (33.3%) showed lower mHbA1c
levels during treatment with MDI (<xref ref-type="table" rid="t2">Table 2</xref>).</p><p>Regarding acute complications, the number of hospitalizations and visits to emergency
services due to hypoglycemic and diabetic ketoacidosis events were recorded during the
two treatment periods.</p><p>During MDI, 15&#x02013;40 patients have hypoglycemic events needing help from other person. From
those 15 patients, 3 had two events, 1 tree events and one, 4 events. No ketoacidosis
events were recorded.</p><p>During CIIT, 5&#x02013;40 patients have hypoglycemic events needing help from other person. From
those 5, only one event by each one was recorded. Again, no ketoacidosis events were
recorded.</p><p>Analysis of the mean number of events showed that more complications occurred during MDI
treatment than during CIIT (<italic>p</italic>=0.021, single-sample nonparametric
Wilcoxon test).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>HbA1c level is the most useful measure for the evaluation of metabolic control and the
only one demonstrating good correlation with vascular complications.<xref rid="B12" ref-type="bibr">12</xref>
<sup>&#x02013;</sup>
<xref rid="B14" ref-type="bibr">14</xref> The process of hemoglobin glycation involves a
permanent bond with reducing sugars such as glucose and, because of this irreversible
bond, HbA1c values correspond to the hyperglycemia levels of DM patients in a more
reliable and true manner than the fasting glycemic levels.</p><p>The DCCT study demonstrated that, when HbA1c exceeds 7.5%, the risk of complications
increases significantly.<xref rid="B12" ref-type="bibr">12</xref>
<sup>&#x02013;</sup>
<xref rid="B14" ref-type="bibr">14</xref> The ISPAD<xref rid="B15" ref-type="bibr">15</xref> recommends a value of HbA1c of less that 7.5%.</p><p>The present study showed that 14.2% of the patients had lower than 7.5% mHbA1c during
the use of MDI, while 35.71% showed an mHbA1c value lower than 7.5% with the use of
CIIT, demonstrating better glycemic control with the use of infusion pump therapy. The
same conclusion was observed when individual analysis cases of patients with mHbA1c
lower than 7.6% in at least one of the treatments (<xref ref-type="table" rid="t2">Table
2</xref>).</p><p>Comparison of the periods of use of MDI and CIIT revealed a reduction of both the mean
(9.1&#x02013;8.9) and the median (8.6&#x02013;8.2) values of HbA1c levels; although these values no
significant difference was observed. Several studies, especially those conducted on
young individuals, have demonstrated that CIIT and MDI induce similar results of
glycemic control.<xref rid="B16" ref-type="bibr">16</xref>
<sup>&#x02013;</sup>
<xref rid="B19" ref-type="bibr">19</xref> In a recent meta-analysis, Yeh et al.<xref rid="B16" ref-type="bibr">16</xref> analyzed 33 randomized and controlled studies
comparing the two therapies in children and adults with T1DM and concluded that most
studies showed similar effects on the control of glycemia in children, with a favorable
effect of the use of CIIT on the reduction of HbA1c levels in adults. However, other
studies have shown that the use of CIIT promotes a reduction of HbA1c levels both in
children<xref rid="B20" ref-type="bibr">20</xref>
<sup>&#x02013;</sup>
<xref rid="B24" ref-type="bibr">24</xref> and in adults.<xref rid="B21" ref-type="bibr">21</xref>
<sup>,</sup>
<xref rid="B22" ref-type="bibr">22</xref>
<sup>,</sup>
<xref rid="B24" ref-type="bibr">24</xref>
</p><p>In view that the time of use of one of the therapies might influence the evaluation of
HbA1c levels, the same analysis of mean and median HbA1c values were performed in
patients with at least 1 year of each treatment. Another analysis was performed in
patients with at least 2 years of each treatment (<xref ref-type="table" rid="t1">Table
1</xref>). However, no significant difference was detected favoring one of the
treatments.</p><p>Regarding adverse effects, a systematic review by Pickup et al.<xref rid="B25" ref-type="bibr">25</xref> showed that the frequency of severe hypoglycemia episodes was
reduced 4.2 times with the use of CIIT, compared to MDI, although other studies did not
detect a significant difference in the number of adverse events between the two
treatments.<xref rid="B20" ref-type="bibr">20</xref>
<sup>&#x02013;</sup>
<xref rid="B22" ref-type="bibr">22</xref>
<sup>,</sup>
<xref rid="B26" ref-type="bibr">26</xref> In the present patient series, there was a
reduction of the frequency of severe hyperglycemic episodes. Similarly to our data, a
previous Brazilian study has also showed reduction of severe hypoglycemia episodes. In
spite of fewer subjects and shorter period of observation, this analysis showed a little
improvement of metabolic control; furthermore, the authors have not compared MDI and
CITT.<xref rid="B27" ref-type="bibr">27</xref> A recent paper showed in 345 patients
a 0.6% reduction of HbA1c levels from injections to insulin pump therapy. The authors
also showed a reduction of severe hypoglycemic events and DKA episodes.<xref rid="B28" ref-type="bibr">28</xref>
</p><p>In the design of the present study, the fact that each patient acted as his own control
eliminated inter individual differences (such as eating habits, patterns of physical
activities, motivation and attitude toward the disease, among others) that might
interfere with the analysis since two samples, even when matched, may show differences.
However, a limitation of the study is the fact that it was not controlled, with a
retrospective and with small sample. Other important issue is the period of observation;
probably longer periods of time could have shown a significant difference in the
metabolic control. Despite these limitations, to the best of our knowledge, this is the
first study with this design comparing the use of two forms of basal-bolus therapy for
the metabolic control of diabetes and of the occurrence of acute complications of the
disease, in Brazil.</p><p>In conclusion, intensive insulin therapy (MDI or CIIT) represents the best form of
treatment in order to obtain adequate metabolic control for T1DM patients. Analysis of
several studies showed that there is no consensus about the choice between MDI and CIIT
for the treatment of T1DM, regarding glycemic control and the rates of adverse events.
The present study is the first in Brazil to compare the two forms of therapy with a
design of patient as self-control, showing improvement in metabolic control with the use
of CIIT, with a reduced occurrence of acute complications of diabetes in this
sample.</p></sec></body><back><fn-group><fn fn-type="supported-by" id="fn1"><p>
<bold>Funding</bold>
</p><p>The study received no funding.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahillo Curieses</surname><given-names>MP</given-names></name><name><surname>Hermoso L&#x000f3;pez</surname><given-names>F</given-names></name><name><surname>Garc&#x000ed;a Fern&#x000e1;ndez</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Epidemiology of type 1 diabetes in children and adolescents aged less
than 15 years in the provinces of Castilla y Le&#x000f3;n</article-title><source>An Pediatric (Barc)</source><year>2006</year><volume>65</volume><fpage>15</fpage><lpage>21</lpage></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><article-title>Variation and trends in incidence of childhood diabetes in
Europe</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>873</fpage><lpage>876</lpage><pub-id pub-id-type="pmid">10752702</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bui</surname><given-names>TP</given-names></name><name><surname>Werther</surname><given-names>GA</given-names></name><name><surname>Cameron</surname><given-names>FJ</given-names></name></person-group><article-title>Trends in diabetic ketoacidosis in childhood and adolescence: a 15-yr
experience</article-title><source>Pediatr Diabetes</source><year>2002</year><volume>3</volume><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">15016161</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The Diabetes Control and Complications Trial Research Group</collab></person-group><article-title>The effect of intensive treatment of diabetes on the development and
progression of long-term complications in insulin-dependent diabetes
mellitus</article-title><source>N Engl J Med</source><year>1993</year><volume>329</volume><fpage>977</fpage><lpage>986</lpage><pub-id pub-id-type="pmid">8366922</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberatore</surname><given-names>Rdel R</given-names><suffix>Jr</suffix></name><name><surname>Damiani</surname><given-names>D</given-names></name></person-group><article-title>Insulin pump therapy in type 1 diabetes mellitus</article-title><source>J Pediatr (Rio J)</source><year>2006</year><volume>82</volume><fpage>249</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">16912828</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malerbi</surname><given-names>D</given-names></name><name><surname>Damiani</surname><given-names>D</given-names></name><name><surname>Rassi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Brazilian diabetes society consensus statement &#x02013; intensive insulin
therapy and insulin pump therapy</article-title><source>Arq Bras Endocrinol Metabol</source><year>2006</year><volume>50</volume><fpage>125</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">16628285</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minicucci</surname><given-names>WJ</given-names></name></person-group><article-title>Insulin pump therapy in patients with type 1 diabetes</article-title><source>Arq Bras Endocrinol Metabol</source><year>2008</year><volume>52</volume><fpage>340</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">18438545</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boland</surname><given-names>EA</given-names></name><name><surname>Grey</surname><given-names>M</given-names></name><name><surname>Oesterle</surname><given-names>A</given-names></name><name><surname>Fredrickson</surname><given-names>L</given-names></name><name><surname>Tamborlane</surname><given-names>WV</given-names></name></person-group><article-title>Continuous subcutaneous insulin infusion: a new way to lower risk of
severe hypoglycemia, improve metabolic control, and enhance coping in adolescents
with type 1 diabetes</article-title><source>Diabetes Care</source><year>1999</year><volume>22</volume><fpage>1779</fpage><lpage>1784</lpage><pub-id pub-id-type="pmid">10546007</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanaire-Broutin</surname><given-names>H</given-names></name><name><surname>Melki</surname><given-names>V</given-names></name><name><surname>Bessi&#x000e8;res-Lacombe</surname><given-names>S</given-names></name><name><surname>Tauber</surname><given-names>JP</given-names></name></person-group><article-title>Comparison of continuous subcutaneous insulin infusion and multiple
daily injection regimens using insulin lispro in type 1 diabetic patients on
intensified treatment</article-title><source>Diabetes Care</source><year>2000</year><volume>23</volume><fpage>1232</fpage><lpage>1235</lpage><pub-id pub-id-type="pmid">10977011</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>FR</given-names></name><name><surname>Halvorson</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Pitukcheewanont</surname><given-names>P</given-names></name></person-group><article-title>Use of insulin pump therapy at nighttime only for children 7&#x02013;10 years
of age with type 1 diabetes</article-title><source>Diabetes Care</source><year>2000</year><volume>23</volume><fpage>579</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">10834412</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casas-O&#x000f1;ate</surname><given-names>ML</given-names></name><name><surname>Montoya-Mart&#x000ed;nez</surname><given-names>D</given-names></name></person-group><article-title>Influence of the treatment with continuous subcutaneous insulin
infusion (CSII) in the improvement of the quality of life of patients with type 1
diabetes mellitus</article-title><source>Enferm Clin</source><year>2010</year><volume>20</volume><fpage>216</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">20561806</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberatore</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Perlman</surname><given-names>K</given-names></name><name><surname>Buccino</surname><given-names>J</given-names></name><name><surname>Artiles-Sisk</surname><given-names>A</given-names></name><name><surname>Daneman</surname><given-names>D</given-names></name></person-group><article-title>Continuous subcutaneous insulin infusion pump treatment in children
with type 1 diabetes mellitus</article-title><source>J Pediatr Endocrinol Metab</source><year>2004</year><volume>17</volume><fpage>223</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">15055358</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><article-title>Effect of intensive diabetes treatment on the development and
progression of long-term complications in adolescents with insulin-dependent
diabetes mellitus: Diabetes Control and Complication Trial Research
Group</article-title><source>J Pediatr</source><year>1994</year><volume>125</volume><fpage>177</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">8040759</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><article-title>Effect of intensive diabetes treatment on the development and
progression of long-term complications in adolescents with insulin-dependent
diabetes mellitus: Diabetes Control and Complication Trial Research
Group</article-title><source>N Engl J Med</source><year>1993</year><volume>329</volume><fpage>977</fpage><lpage>986</lpage><pub-id pub-id-type="pmid">8366922</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couper</surname><given-names>J</given-names></name><name><surname>Donaghue</surname><given-names>K</given-names></name></person-group><article-title>International society for pediatric and adolescent diabetes. Phases of
diabetes</article-title><source>Pediatr Diabetes</source><year>2007</year><volume>8</volume><fpage>44</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">17341290</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>HC</given-names></name><name><surname>Brown</surname><given-names>TT</given-names></name><name><surname>Maruthur</surname><given-names>N</given-names></name><etal/></person-group><article-title>Comparative effectiveness and safety of methods of insulin delivery
and glucose monitoring for diabetes mellitus: a systematic review and
meta-analysis</article-title><source>Ann Intern Med</source><year>2012</year><volume>10</volume><comment>E-508</comment></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abaci</surname><given-names>A</given-names></name><name><surname>Atas</surname><given-names>A</given-names></name><name><surname>Unuvar</surname><given-names>T</given-names></name><name><surname>Demir</surname><given-names>K</given-names></name><name><surname>Bober</surname><given-names>E</given-names></name><name><surname>B&#x000fc;y&#x000fc;kgebiz</surname><given-names>A</given-names></name></person-group><article-title>A comparison of multiple daily insulin therapy with continuous
subcutaneous insulin infusion therapy in adolescents with type 1 diabetes
mellitus: a single-center experience from Turkey</article-title><source>J Pediatr Endocrinol Metab</source><year>2009</year><volume>22</volume><fpage>539</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">19694201</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodvarsdottir</surname><given-names>KO</given-names></name><name><surname>Aspelund</surname><given-names>T</given-names></name><name><surname>Gudmundsdottir</surname><given-names>A</given-names></name></person-group><article-title>Treatment of type 1 diabetes with continuous subcutaneous insulin
infusion (CSII) in adults in Iceland</article-title><source>Laeknabladid</source><year>2011</year><volume>97</volume><fpage>291</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">21586800</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nahata</surname><given-names>L</given-names></name></person-group><article-title>Insulin therapy in pediatric patients with type I diabetes: continuous
subcutaneous insulin infusion versus multiple daily injections</article-title><source>Clin Pediatr (Phila)</source><year>2006</year><volume>45</volume><fpage>503</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">16893854</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pa&#x00144;kowska</surname><given-names>E</given-names></name><name><surname>B&#x00142;azik</surname><given-names>M</given-names></name><name><surname>Dziechciarz</surname><given-names>P</given-names></name><name><surname>Szypowska</surname><given-names>A</given-names></name><name><surname>Szajewska</surname><given-names>H</given-names></name></person-group><article-title>Continuous subcutaneous insulin infusion vs. multiple daily injections
in children with type 1 diabetes: a systematic review and meta-analysis of
randomized control trials</article-title><source>Pediatr Diabetes</source><year>2009</year><volume>10</volume><fpage>52</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">18761648</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeitler</surname><given-names>K</given-names></name><name><surname>Horvath</surname><given-names>K</given-names></name><name><surname>Berghold</surname><given-names>A</given-names></name><etal/></person-group><article-title>Continuous subcutaneous insulin infusion versus multiple daily insulin
injections in patients with diabetes mellitus: systematic review and
meta-analysis</article-title><source>Diabetologia</source><year>2008</year><volume>51</volume><fpage>941</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">18351320</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Retnakaran</surname><given-names>R</given-names></name><name><surname>Hochman</surname><given-names>J</given-names></name><name><surname>DeVries</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Continuous subcutaneous insulin infusion versus multiple daily
injections: the impact of baseline A1c</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>2590</fpage><lpage>2596</lpage><pub-id pub-id-type="pmid">15504991</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasselmann</surname><given-names>C</given-names></name><name><surname>Bonnemaison</surname><given-names>E</given-names></name><name><surname>Faure</surname><given-names>N</given-names></name><etal/></person-group><article-title>Benefits of continuous subcutaneous insulin infusion in children with
type 1 diabetes mellitus</article-title><source>Arch Pediatr</source><year>2012</year><volume>19</volume><fpage>593</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">22584198</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colquitt</surname><given-names>JL</given-names></name><name><surname>Green</surname><given-names>C</given-names></name><name><surname>Sidhu</surname><given-names>MK</given-names></name><name><surname>Hartwell</surname><given-names>D</given-names></name><name><surname>Waugh</surname><given-names>N</given-names></name></person-group><article-title>Clinical and cost-effectiveness of continuous subcutaneous insulin
infusion for diabetes</article-title><source>Health Technol Assess</source><year>2004</year><volume>8</volume><fpage>1</fpage><lpage>171</lpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pickup</surname><given-names>JC</given-names></name><name><surname>Sutton</surname><given-names>AJ</given-names></name></person-group><article-title>Severe hypoglycaemia and glycaemic control in type 1 diabetes:
meta-analysis of multiple daily insulin injections compared with continuous
subcutaneous insulin infusion</article-title><source>Diabet Med</source><year>2008</year><volume>25</volume><fpage>765</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">18644063</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fatourechi</surname><given-names>MM</given-names></name><name><surname>Kudva</surname><given-names>YC</given-names></name><name><surname>Murad</surname><given-names>MH</given-names></name><name><surname>Elamin</surname><given-names>MB</given-names></name><name><surname>Tabini</surname><given-names>CC</given-names></name><name><surname>Montori</surname><given-names>VM</given-names></name></person-group><article-title>Clinical review: hypoglycemia with intensive insulin therapy: a
systematic review and meta-analyses of randomized trials of continuous
subcutaneous insulin infusion versus multiple daily injections</article-title><source>J Clin Endocrinol Metab</source><year>2009</year><volume>94</volume><fpage>729</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">19088167</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabbay</surname><given-names>MA</given-names></name><name><surname>Dib</surname><given-names>SA</given-names></name></person-group><article-title>Comparison between continuous subcutaneous insulin infusion and
multiple daily injection regimens in adolescent with type 1 diabetes from a public
health care system approach to severe hypoglycemia</article-title><source>Arq Bras Endocrinol Metabol</source><year>2007</year><volume>51</volume><fpage>1169</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">18157395</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>SR</given-names></name><name><surname>Cooper</surname><given-names>MN</given-names></name><name><surname>Jones</surname><given-names>TW</given-names></name><name><surname>Davis</surname><given-names>EA</given-names></name></person-group><article-title>Long-term outcome of insulin pump therapy in children with type 1
diabetes assessed in a large population-based case&#x02013;control study</article-title><source>Diabetologia</source><year>2013</year><volume>56</volume><fpage>2392</fpage><lpage>2400</lpage><pub-id pub-id-type="pmid">23963323</pub-id></element-citation></ref></ref-list></back><sub-article id="SA1" article-type="translation" xml:lang="pt"><front-stub><title-group><article-title>Insulinoterapia cont&#x000ed;nua versus m&#x000fa;ltiplas inje&#x000e7;&#x000f5;es de insulina no
tratamento da diabetes tipo 1: um estudo longitudinal</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ribeiro</surname><given-names>Maria Estela Bellini</given-names></name></contrib><contrib contrib-type="author"><name><surname>Liberatore</surname><given-names>Raphael Del Roio</given-names><suffix>Junior</suffix></name><xref ref-type="corresp" rid="c2">*</xref></contrib><contrib contrib-type="author"><name><surname>Custodio</surname><given-names>Rodrigo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Martinelli</surname><given-names>Carlos Eduardo</given-names><suffix>Junior</suffix></name></contrib><aff>Universidade de S&#x000e3;o Paulo (USP), Ribeir&#x000e3;o Preto, SP, Brasil</aff></contrib-group><author-notes><corresp id="c2"><label>*</label> Autor para correspond&#x000ea;ncia. <email>rliberatore@fmrp.usp.br</email>
(R. Del Roio Liberatore Junior).</corresp><fn fn-type="conflict"><p>
<bold>Conflitos de interesse</bold>
</p><p>Os autores declaram n&#x000e3;o ter conflitos de interesse.</p></fn></author-notes><abstract><title>Resumo</title><sec><title>Objetivo:</title><p>Comparar terapia com m&#x000fa;ltiplas doses de insulina e o sistema de infus&#x000e3;o continua
de insulina no tratamento da diabetes melito tipo 1.</p></sec><sec><title>M&#x000e9;todos:</title><p>40 pacientes com diabetes melito tipo 1 (21 mulheres) com idades entre 10 e 20
anos (m&#x000e9;dia=14,2) e dura&#x000e7;&#x000e3;o m&#x000e9;dia do diabetes de sete anos utilizaram m&#x000fa;ltiplas
doses de insulina durante pelo menos seis meses e, depois disso, sistema de
infus&#x000e3;o continua de insulina por pelo menos seis meses. Todos os pacientes usaram
m&#x000fa;ltiplas doses de insulina e sistema de infus&#x000e3;o continua de insulina. Para a
an&#x000e1;lise de HbA1c, n&#x000ed;veis m&#x000e9;dios de hemoglobina glicada (mHbA1c) foram obtidos em
cada per&#x000ed;odo de tratamento (m&#x000fa;ltiplas doses de insulina e sistema de infus&#x000e3;o
continua de insulina).</p></sec><sec><title>Resultados:</title><p>Embora os n&#x000ed;veis de mHbA1c tenham sido menores com o uso de sistema de infus&#x000e3;o
continua de insulina a diferen&#x000e7;a n&#x000e3;o foi estatisticamente significante. Durante o
uso de m&#x000fa;ltiplas doses de insulina, 14,2% tiveram valores de mHbA1c &#x0003c;7,5% vs.
35,71% quando usando sistema de infus&#x000e3;o continua de insulina; demonstrando melhor
controle glic&#x000ea;mico com o uso de sistema de infus&#x000e3;o continua de insulina. Durante o
uso de m&#x000fa;ltiplas doses de insulina, 15-40 pacientes tiveram eventos hipoglic&#x000ea;micos
graves contra 5&#x02013;40 com sistema de infus&#x000e3;o continua de insulina. N&#x000e3;o foram
registrados epis&#x000f3;dios de cetoacidose.</p></sec><sec><title>Conclus&#x000f5;es:</title><p>Esse &#x000e9; o primeiro estudo cujo desenho comparou o uso de m&#x000fa;ltiplas doses de
insulina e sistema de infus&#x000e3;o continua de insulina no Brasil, n&#x000e3;o demonstrando
nenhuma diferen&#x000e7;a significativa nos n&#x000ed;veis de HbA1c. Eventos hipoglic&#x000ea;micos foram
menos frequentes com o uso de sistema de infus&#x000e3;o continua de insulina do que com
m&#x000fa;ltiplas doses de insulina e a porcentagem de pacientes que obteve um HbA1c
&#x0003c;7,5% foi maior com sistema de infus&#x000e3;o continua de insulina do que com
m&#x000fa;ltiplas doses de insulina.</p></sec></abstract><kwd-group><title>PALAVRAS-CHAVE</title><kwd>Diabetes melito tipo 1</kwd><kwd>Insulina</kwd><kwd>Sistemas de infus&#x000e3;o de insulina</kwd><kwd>Adolescentes</kwd></kwd-group></front-stub><body><sec><title>Introdu&#x000e7;&#x000e3;o</title><p>Diabetes melito (DM) &#x000e9; uma s&#x000ed;ndrome metab&#x000f3;lica cr&#x000f4;nica caracterizada por intenso
catabolismo. Diabetes melito tipo 1 (DM1) ocorre devido &#x000e0; secre&#x000e7;&#x000e3;o deficiente de
insulina, na maioria dos casos ap&#x000f3;s a destrui&#x000e7;&#x000e3;o autoimune das c&#x000e9;lulas beta
pancre&#x000e1;ticas. &#x000c9; uma doen&#x000e7;a cr&#x000f4;nica muito frequente que afeta crian&#x000e7;as,<xref rid="B1" ref-type="bibr">1</xref> com uma incid&#x000ea;ncia crescente em todo o
mundo.<xref rid="B2" ref-type="bibr">2</xref> Dessa forma, a cetoacidose diab&#x000e9;tica
(CAD) e a hipoglicemia s&#x000e3;o complica&#x000e7;&#x000f5;es agudas da DM1 associadas com v&#x000e1;rios efeitos
adversos, e ambas podem ter efeitos fatais se n&#x000e3;o forem revertidas a tempo.<xref rid="B3" ref-type="bibr">3</xref>
</p><p>O estudo DCCT (The Diabetes Control and Complications Trial Research Group)<xref rid="B4" ref-type="bibr">4</xref> demonstrou que a terapia insul&#x000ed;nica intensiva
com m&#x000fa;ltiplas doses de insulina (MDI) ou o sistema de infus&#x000e3;o cont&#x000ed;nua (SIC) de
insulina seria o melhor tratamento para a DM1. Apesar do conhecimento sobre ambos,
MDI<xref rid="B5" ref-type="bibr">5</xref>
<sup>&#x02013;</sup>
<xref rid="B7" ref-type="bibr">7</xref> e SIC,<xref rid="B7" ref-type="bibr">7</xref>
a compara&#x000e7;&#x000e3;o entre esses esquemas terap&#x000ea;uticos, especialmente entre as crian&#x000e7;as e
adolescentes, &#x000e9; incipiente. V&#x000e1;rios estudos t&#x000ea;m sugerido que o SIC pode proporcionar
um melhor controle glic&#x000ea;mico,<xref rid="B8" ref-type="bibr">8</xref>
<sup>&#x02013;</sup>
<xref rid="B11" ref-type="bibr">11</xref> com menor risco de hipoglicemia grave, e
menor ganho de peso em compara&#x000e7;&#x000e3;o com a terapia com MDI. Entre essas an&#x000e1;lises, poucos
desses trabalhos foram realizados em crian&#x000e7;as e adolescentes.<xref rid="B9" ref-type="bibr">9</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">10</xref>
</p><p>O objetivo do presente estudo foi avaliar, de forma comparativa, a terapia com MDI e
o uso do SIC sobre o controle metab&#x000f3;lico e a ocorr&#x000ea;ncia de complica&#x000e7;&#x000f5;es agudas da
doen&#x000e7;a em uma amostra de crian&#x000e7;as e adolescentes com DM1, acompanhados em um hospital
p&#x000fa;blico no estado de S&#x000e3;o Paulo, Brasil.</p></sec><sec><title>M&#x000e9;todo</title><p>Este foi um estudo longitudinal baseado em dados obtidos retrospectivamente dos
prontu&#x000e1;rios de pacientes de ambos os sexos com idade entre 5 e 20 anos com
diagn&#x000f3;stico de DM1, de acordo com os crit&#x000e9;rios da International Society for Pediatric
and Adolescent Diabetes (ISPAD, 1995).</p><p>Os pacientes usaram MDI por pelo menos 6 meses, e depois o SIC, usando ambas as
marcas dispon&#x000ed;veis no Brasil, tamb&#x000e9;m por pelo menos 6 meses. A dura&#x000e7;&#x000e3;o da diabetes
deveria ser maior do que dois anos.</p><p>Todos os pacientes foram treinados para contar carboidratos, modificar a dose de
insulina e medir os n&#x000ed;veis de glicose capilar de 7 a 9 vezes ao dia. Todos eles
tinham um n&#x000fa;mero de telefone para fazer contato em caso de necessidade, e as
consultas eram feitas a cada 3 meses por uma equipe multiprofissional.</p><p>Os seguintes dados foram obtidos: sexo, idade, tempo de uso da terapia com MDI, tempo
de uso do SIC, n&#x000ed;veis m&#x000e9;dios de hemoglobina glicada (mHbA1c), n&#x000fa;mero de eventos
hipoglic&#x000ea;micos graves necessitando de ajuda para a recupera&#x000e7;&#x000e3;o, e n&#x000fa;mero de epis&#x000f3;dios
de CAD. Os n&#x000ed;veis de HbA1c foram medidos por cromatografia l&#x000ed;quida de alta efici&#x000ea;ncia
(CLAE) e o mesmo m&#x000e9;todo foi adotado durante todo o estudo.</p><p>O protocolo de pesquisa foi aprovado pelo Comit&#x000ea; de &#x000c9;tica em Pesquisa com dispensa do
consentimento informado.</p><p>Os dados s&#x000e3;o apresentados como m&#x000e9;dia (&#x000b1;DP) e mediana. O teste n&#x000e3;o param&#x000e9;trico de
Wilcoxon foi utilizado para os valores das vari&#x000e1;veis pareadas, com n&#x000ed;vel de
signific&#x000e2;ncia de <italic>p</italic>&#x0003c;0,05.</p></sec><sec><title>Resultados</title><p>Foram analisados os prontu&#x000e1;rios de 40 pacientes, 46,4% deles do sexo masculino, que
utilizaram primeiro a terapia com MDI e depois o SIC durante o per&#x000ed;odo de 2011 a
2012. No momento da coleta de dados, a idade dos pacientes variou de 10 anos e oito
meses a 20 anos e 2 meses (m&#x000e9;dia&#x000b1;desvio padr&#x000e3;o: 14&#x000b1;2,35 anos). O tempo desde o
diagn&#x000f3;stico da doen&#x000e7;a variou de 2 anos e 2 meses a 15 anos e 3 meses (m&#x000e9;dia de 7,0
anos).</p><p>O tempo de uso da terapia com MDI variou de 8 meses a 14 anos e 9 meses (m&#x000e9;dia&#x000b1;desvio
padr&#x000e3;o: 5,1&#x000b1;3,6 meses). O tempo de uso do SIC variou de 6 meses a 4 anos e 5 meses
(m&#x000e9;dia&#x000b1;desvio padr&#x000e3;o: 1,4&#x000b1;3,6 anos) (<xref ref-type="table" rid="t3">tabela
1</xref>).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Tabela 1</label><caption><title>Valores m&#x000e9;dios de hemoglobina glicada (mHbA1c) (%) para a amostra total
(T), hemoglobina glicada m&#x000e9;dia para os pacientes que foram submetidos a pelo
menos 1 ano de cada tratamento (1a) e 2 anos de cada tratamento (2a)</title></caption><table frame="hsides" rules="groups" style="border-color:#376bad"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead style="background-color:#bad2ed;border-color:#376bad"><tr><th align="left" rowspan="1" colspan="1">mHbA1c (n=40)</th><th align="left" rowspan="1" colspan="1">M&#x000e9;dia&#x000b1;DP</th><th align="left" rowspan="1" colspan="1">Mediana</th><th align="left" rowspan="1" colspan="1">
<italic>p</italic> &#x02010;valor <xref ref-type="table-fn" rid="TFN7">a</xref>
</th></tr></thead><tbody style="background-color:#e5edf8;border-color:#376bad"><tr><td align="left" rowspan="1" colspan="1">MDI (T)</td><td align="char" rowspan="1" colspan="1">9,1&#x000b1;2.0</td><td align="char" rowspan="1" colspan="1">8,6</td><td align="char" rowspan="1" colspan="1">0,55 <xref ref-type="table-fn" rid="TFN8">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">SIC (T)</td><td align="char" rowspan="1" colspan="1">8,9&#x000b1;2.5</td><td align="char" rowspan="1" colspan="1">8,2</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">MDI (1 a)</td><td align="char" rowspan="1" colspan="1">9,3&#x000b1;2.3</td><td align="char" rowspan="1" colspan="1">8,6</td><td align="char" rowspan="1" colspan="1">0,095 <xref ref-type="table-fn" rid="TFN9">c</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">SIC (1 a)</td><td align="char" rowspan="1" colspan="1">8,4&#x000b1;1.9</td><td align="char" rowspan="1" colspan="1">7,8</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">MDI (2 a)</td><td align="char" rowspan="1" colspan="1">8,4&#x000b1;0.9</td><td align="char" rowspan="1" colspan="1">8,4</td><td align="char" rowspan="1" colspan="1">0,67 <xref ref-type="table-fn" rid="TFN10">d</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">SIC (2 a)</td><td align="char" rowspan="1" colspan="1">8,4&#x000b1;2.3</td><td align="char" rowspan="1" colspan="1">7,7</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TFN7"><label>a</label><p>Teste n&#x000e3;o param&#x000e9;trico de Wilcoxon &#x02013; amostra &#x000fa;nica.</p></fn><fn id="TFN8"><label>b</label><p>Compara&#x000e7;&#x000e3;o entre MDI e SIC.</p></fn><fn id="TFN9"><label>c</label><p>Compara&#x000e7;&#x000e3;o entre MDI e SIC (1a).</p></fn><fn id="TFN10"><label>d</label><p>Compara&#x000e7;&#x000e3;o entre MDI e SIC (2a).</p></fn><fn id="TFN11"><p>DP, desvio padr&#x000e3;o; MDI, m&#x000fa;ltiplas doses de insulina; SIC, sistema de infus&#x000e3;o
cont&#x000ed;nua de insulina.</p></fn></table-wrap-foot></table-wrap><p>Os dados n&#x000e3;o apresentaram varia&#x000e7;&#x000e3;o de acordo com o sexo.</p><p>Para a an&#x000e1;lise de n&#x000ed;veis de HbA1c, os resultados obtidos durante cada per&#x000ed;odo de
tratamento (MDI e SIC) foram recuperados e o valor da mHbA1c foi calculado para cada
paciente e para cada per&#x000ed;odo. A m&#x000e9;dia e a mediana da mHbA1c foram ent&#x000e3;o calculadas
para a amostra e para o per&#x000ed;odo de cada tratamento. A <xref ref-type="table" rid="t4">tabela 2</xref> mostra os resultados obtidos da mHbA1c nos dois per&#x000ed;odos. Os
dados mostram que, embora os n&#x000ed;veis de mHbA1c tenham sido menores durante a
utiliza&#x000e7;&#x000e3;o do SIC do que durante a utiliza&#x000e7;&#x000e3;o do MDI, n&#x000e3;o foi observada diferen&#x000e7;a
significativa.</p><table-wrap id="t4" orientation="portrait" position="float"><label>Tabela 2</label><caption><title>Valores m&#x000e9;dios de hemoglobina glicada (mHbA1c) (%) para pacientes com
n&#x000ed;veis inferiores a 7,5% durante apenas um dos tratamentos</title></caption><table frame="hsides" rules="groups" style="border-color:#376bad"><colgroup span="1"><col width="40%" span="1"/><col width="30%" span="1"/><col width="30%" span="1"/></colgroup><thead style="background-color:#bad2ed;border-color:#376bad"><tr><th align="left" rowspan="1" colspan="1">Paciente</th><th align="left" rowspan="1" colspan="1">mHbA1c durante MDI</th><th align="left" rowspan="1" colspan="1">mHbA1c durante SIC</th></tr></thead><tbody style="background-color:#e5edf8;border-color:#376bad"><tr><td align="left" rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1">7,85</td><td align="char" rowspan="1" colspan="1">7,1</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="char" rowspan="1" colspan="1">7,96</td><td align="char" rowspan="1" colspan="1">7,33</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="char" rowspan="1" colspan="1">7,9</td><td align="char" rowspan="1" colspan="1">6,87</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="char" rowspan="1" colspan="1">9,45</td><td align="char" rowspan="1" colspan="1">7,26</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="char" rowspan="1" colspan="1">8,33</td><td align="char" rowspan="1" colspan="1">7,26</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="char" rowspan="1" colspan="1">8,4</td><td align="char" rowspan="1" colspan="1">5,35</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="char" rowspan="1" colspan="1">8,61</td><td align="char" rowspan="1" colspan="1">7,5</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="char" rowspan="1" colspan="1">9,3</td><td align="char" rowspan="1" colspan="1">7,05</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="char" rowspan="1" colspan="1">7,1</td><td align="char" rowspan="1" colspan="1">7,5</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="char" rowspan="1" colspan="1">7,06</td><td align="char" rowspan="1" colspan="1">7,7</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="char" rowspan="1" colspan="1">7,1</td><td align="char" rowspan="1" colspan="1">7,8</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="char" rowspan="1" colspan="1">7,1</td><td align="char" rowspan="1" colspan="1">7,5</td></tr></tbody></table><table-wrap-foot><fn id="TFN12"><p>mHba1c, hemoglobina glicada m&#x000e9;dia para cada paciente; MDI, m&#x000fa;ltiplas
inje&#x000e7;&#x000f5;es di&#x000e1;rias de insulina; SIC, sistema de infus&#x000e3;o cont&#x000ed;nua de
insulina.</p></fn></table-wrap-foot></table-wrap><p>A an&#x000e1;lise dos dados para os pacientes que tinham utilizado cada tratamento por pelo
menos um ano revelou que os n&#x000ed;veis de mHbA1c foram de 9,3 (&#x000b1;2,3)% durante o per&#x000ed;odo
com MDI (mediana: 8,6), e 8,4 (&#x000b1;1,9)% durante o per&#x000ed;odo com SIC, com uma mediana de
7,8% (<italic>p</italic>=0,095), indicando que n&#x000e3;o houve nenhuma diferen&#x000e7;a
significativa nos n&#x000ed;veis de mHbA1c obtidos durante os dois tratamentos (<xref ref-type="table" rid="t3">tabela 1</xref>).</p><p>A an&#x000e1;lise dos dados para os pacientes que tinham utilizado cada tratamento por pelo
menos dois anos revelou que os n&#x000ed;veis de mHbA1c foram de 8,4 (&#x000b1;0,9%) durante o
per&#x000ed;odo de MDI, com mediana de 8,4, e 8,4 (&#x000b1;2,3%), e mediana de 7,7%, durante o
per&#x000ed;odo de utiliza&#x000e7;&#x000e3;o do SIC. Mais uma vez, o teste de Wilcoxon n&#x000e3;o mostrou nenhuma
diferen&#x000e7;a significativa entre os per&#x000ed;odos (<italic>p</italic>=0,67) (<xref ref-type="table" rid="t3">tabela 1</xref>).</p><p>Durante a utiliza&#x000e7;&#x000e3;o de MDI, 14,2% dos pacientes apresentaram valores de mHbA1c
abaixo de 7,5%, valor recomendado pelo ISPAD como a meta para o controle metab&#x000f3;lico,
e durante a utiliza&#x000e7;&#x000e3;o do SIC, 35,71% apresentaram valores de mHbA1c abaixo de 7,5%,
o que demonstra um melhor controle glic&#x000ea;mico com o uso de uma bomba de infus&#x000e3;o para o
tratamento.</p><p>A an&#x000e1;lise dos casos com menos de 7,5% nos n&#x000ed;veis de mHbA1c em apenas um dos
tratamentos (MDI ou SIC) revelou que oito dos 12 pacientes (66,6%) apresentaram
n&#x000ed;veis de mHbA1c reduzidos quando mudaram para o SIC, enquanto quatro pacientes
(33,3%) apresentaram n&#x000ed;veis mais baixos de mHbA1c durante o tratamento com MDI (<xref ref-type="table" rid="t4">tabela 2</xref>).</p><p>Quanto &#x000e0;s complica&#x000e7;&#x000f5;es agudas, foram registrados os n&#x000fa;meros de interna&#x000e7;&#x000f5;es e
atendimentos nos servi&#x000e7;os de emerg&#x000ea;ncia devido a eventos hipoglic&#x000ea;micos e cetoacidose
diab&#x000e9;tica durante os dois per&#x000ed;odos de tratamento.</p><p>Durante a terapia com MDI, 15 a 40 pacientes apresentaram eventos hipoglic&#x000ea;micos com
necessidade de ajuda de outra pessoa. Desses 15 pacientes, tr&#x000ea;s tiveram dois eventos,
1 tr&#x000ea;s eventos e outro, 4 eventos. N&#x000e3;o foram registrados eventos de cetoacidose.</p><p>Durante o uso do SIC, 5 a 40 pacientes apresentaram eventos hipoglic&#x000ea;micos com
necessidade de ajuda de outra pessoa. Desses cinco, apenas um evento foi registrado
para cada um. Mais uma vez, n&#x000e3;o foram registrados eventos de cetoacidose.</p><p>A an&#x000e1;lise do n&#x000fa;mero m&#x000e9;dio de eventos mostrou que mais complica&#x000e7;&#x000f5;es ocorreram durante
o tratamento com MDI do que com o SIC (<italic>p</italic>=0,021, teste de Wilcoxon
n&#x000e3;o param&#x000e9;trico de amostra &#x000fa;nica).</p></sec><sec><title>Discuss&#x000e3;o</title><p>O n&#x000ed;vel de HbA1c &#x000e9; a medida mais &#x000fa;til para a avalia&#x000e7;&#x000e3;o do controle metab&#x000f3;lico e o
&#x000fa;nico que demonstra boa correla&#x000e7;&#x000e3;o com complica&#x000e7;&#x000f5;es vasculares.<xref rid="B12" ref-type="bibr">12</xref>
<sup>&#x02013;</sup>
<xref rid="B14" ref-type="bibr">14</xref> O processo de glica&#x000e7;&#x000e3;o da hemoglobina
envolve uma liga&#x000e7;&#x000e3;o permanente com a&#x000e7;&#x000fa;cares redutores como a glicose e, devido a essa
liga&#x000e7;&#x000e3;o irrevers&#x000ed;vel, os valores de HbA1c correspondem aos n&#x000ed;veis de hiperglicemia de
pacientes com DM de uma maneira mais confi&#x000e1;vel e verdadeira do que os n&#x000ed;veis
glic&#x000ea;micos de jejum.</p><p>O estudo DCCT demonstrou que, quando a HbA1c excede 7,5%, o risco de complica&#x000e7;&#x000f5;es
aumenta significativamente.<xref rid="B12" ref-type="bibr">12</xref>
<sup>&#x02013;</sup>
<xref rid="B14" ref-type="bibr">14</xref> O ISPAD<xref rid="B15" ref-type="bibr">15</xref> recomenda um valor de HbA1c menor que 7,5%.</p><p>O presente estudo mostrou que 14,2% dos pacientes apresentou um valor de mHbA1c menor
do que 7,5% durante a utiliza&#x000e7;&#x000e3;o de MDI, enquanto 35,71% mostrou um valor mHbA1c
inferior a 7,5% com o uso do SIC, demonstrando um melhor controle glic&#x000ea;mico com o uso
de bombas de infus&#x000e3;o. A mesma conclus&#x000e3;o foi observada em an&#x000e1;lises individuais de
casos de pacientes com mHbA1c inferior a 7,6% em pelo menos um dos tratamentos (<xref ref-type="table" rid="t4">tabela 2</xref>).</p><p>A compara&#x000e7;&#x000e3;o dos per&#x000ed;odos de utiliza&#x000e7;&#x000e3;o de MDI e SIC revelou uma redu&#x000e7;&#x000e3;o dos n&#x000ed;veis
de HbA1c tanto nos valores da m&#x000e9;dia (9,1-8,9) quanto da mediana (8,6-8,2); apesar
desses valores, n&#x000e3;o foi observada uma diferen&#x000e7;a significativa. Diversos estudos,
especialmente aqueles realizados em indiv&#x000ed;duos jovens, demonstraram que o SIC e a
terapia com MDI induzem resultados semelhantes de controle glic&#x000ea;mico.<xref rid="B16" ref-type="bibr">16</xref>
<sup>&#x02013;</sup>
<xref rid="B19" ref-type="bibr">19</xref> Em uma meta-an&#x000e1;lise recente, Yeh et
al.<xref rid="B16" ref-type="bibr">16</xref> analisaram 33 estudos randomizados e
controlados, comparando as duas terapias em crian&#x000e7;as e adultos com DM1, e conclu&#x000ed;ram
que a maioria dos estudos mostrou efeitos semelhantes no controle da glicemia em
crian&#x000e7;as, com um efeito favor&#x000e1;vel do uso do SIC sobre a redu&#x000e7;&#x000e3;o dos n&#x000ed;veis de HbA1c
em adultos. No entanto, outros estudos mostraram que a utiliza&#x000e7;&#x000e3;o do SIC promove a
redu&#x000e7;&#x000e3;o dos n&#x000ed;veis de HbA1c tanto em crian&#x000e7;as<xref rid="B20" ref-type="bibr">20</xref>
<sup>&#x02013;</sup>
<xref rid="B24" ref-type="bibr">24</xref> quanto em adultos.<xref rid="B21" ref-type="bibr">21</xref>
<sup>,</sup>
<xref rid="B22" ref-type="bibr">22</xref>
<sup>,</sup>
<xref rid="B24" ref-type="bibr">24</xref>
</p><p>Tendo em conta que o tempo de utiliza&#x000e7;&#x000e3;o de uma das terapias possa influenciar a
avalia&#x000e7;&#x000e3;o dos n&#x000ed;veis de HbA1c, a mesma an&#x000e1;lise dos valores da mediana e da m&#x000e9;dia de
HbA1c foi realizada em pacientes com pelo menos 1 ano de cada tratamento. Outra
an&#x000e1;lise foi realizada em pacientes com, pelo menos, dois anos de cada tratamento
(<xref ref-type="table" rid="t3">tabela 1</xref>). No entanto, nenhuma diferen&#x000e7;a
significativa foi detectada favorecendo um dos tratamentos.</p><p>Com rela&#x000e7;&#x000e3;o aos efeitos adversos, uma revis&#x000e3;o sistem&#x000e1;tica realizada por Pickup et
al.<xref rid="B25" ref-type="bibr">25</xref> mostrou que a frequ&#x000ea;ncia de epis&#x000f3;dios
de hipoglicemia grave foi reduzida 4,2 vezes com o uso de SIC, em compara&#x000e7;&#x000e3;o com MDI,
embora outros estudos n&#x000e3;o tenham detectado uma diferen&#x000e7;a significativa no n&#x000fa;mero de
eventos adversos entre os dois tratamentos.<xref rid="B20" ref-type="bibr">20</xref>
<sup>&#x02013;</sup>
<xref rid="B22" ref-type="bibr">22</xref>
<sup>,</sup>
<xref rid="B26" ref-type="bibr">26</xref> Na presente s&#x000e9;rie de pacientes houve uma
redu&#x000e7;&#x000e3;o da frequ&#x000ea;ncia de epis&#x000f3;dios hiperglic&#x000ea;micos graves. De forma similar aos
nossos dados, um estudo brasileiro anterior tamb&#x000e9;m mostrou redu&#x000e7;&#x000e3;o dos epis&#x000f3;dios de
hipoglicemia grave. Apesar do n&#x000fa;mero menor de indiv&#x000ed;duos e per&#x000ed;odo de observa&#x000e7;&#x000e3;o mais
curto, essa an&#x000e1;lise mostrou uma pequena melhora do controle metab&#x000f3;lico; al&#x000e9;m disso,
os autores n&#x000e3;o compararam MDI e SIC.<xref rid="B27" ref-type="bibr">27</xref> Um
estudo recente mostrou em 345 pacientes uma redu&#x000e7;&#x000e3;o de 0,6% dos n&#x000ed;veis de HbA1c que
mudaram do tratamento com inje&#x000e7;&#x000f5;es para a bomba de insulina. Os autores tamb&#x000e9;m
mostraram uma redu&#x000e7;&#x000e3;o de eventos hipoglic&#x000ea;micos graves e epis&#x000f3;dios de CAD.<xref rid="B28" ref-type="bibr">28</xref>
</p><p>No desenho do presente estudo, o fato de que cada paciente atuou como seu pr&#x000f3;prio
controle, eliminou as diferen&#x000e7;as interindividuais (tais como h&#x000e1;bitos alimentares,
padr&#x000f5;es de atividade f&#x000ed;sica, motiva&#x000e7;&#x000e3;o e atitude em rela&#x000e7;&#x000e3;o &#x000e0; doen&#x000e7;a, entre outros),
que podiam interferir com a an&#x000e1;lise, j&#x000e1; que duas amostras, mesmo quando pareadas,
podem apresentar diferen&#x000e7;as. No entanto, uma limita&#x000e7;&#x000e3;o do estudo &#x000e9; o fato de que ele
n&#x000e3;o foi controlado, com uma amostra retrospectiva e pequena. Outra quest&#x000e3;o importante
&#x000e9; o per&#x000ed;odo de observa&#x000e7;&#x000e3;o; provavelmente per&#x000ed;odos de tempo mais longos poderiam ter
mostrado uma diferen&#x000e7;a significativa no controle metab&#x000f3;lico. Apesar dessas
limita&#x000e7;&#x000f5;es, que seja de nosso conhecimento, este &#x000e9; o primeiro estudo com esse desenho
comparando o uso de duas formas de terapia basal-bolus para o controle metab&#x000f3;lico da
diabetes e a ocorr&#x000ea;ncia de complica&#x000e7;&#x000f5;es agudas da doen&#x000e7;a, no Brasil.</p><p>Em conclus&#x000e3;o, a terapia intensiva de insulina (com MDI ou SIC) representa a melhor
forma de tratamento com o objetivo de obter o controle metab&#x000f3;lico adequado para
pacientes com DM1. A an&#x000e1;lise de v&#x000e1;rios estudos mostrou que n&#x000e3;o h&#x000e1; consenso sobre a
escolha entre MDI e SIC para o tratamento da DM1, em rela&#x000e7;&#x000e3;o ao controle glic&#x000ea;mico e
&#x000e0;s taxas de eventos adversos. O presente estudo &#x000e9; o primeiro no Brasil a comparar as
duas formas de terapia com um desenho utilizando o pr&#x000f3;prio paciente como
autocontrole, mostrando melhora do controle metab&#x000f3;lico com o uso de SIC, com uma
menor ocorr&#x000ea;ncia de complica&#x000e7;&#x000f5;es agudas da diabetes nesta amostra.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p>
<bold>Financiamento</bold>
</p><p>Este estudo n&#x000e3;o recebeu financiamento.</p></fn></fn-group></back></sub-article></article>